Karyopharm Therapeutics Investor Relations Material
Latest events
AGM 2025
Karyopharm Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Karyopharm Therapeutics Inc
Access all reports
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm Therapeutics develops therapeutic drug products based on an innovative drug delivery technology that has the potential to improve drug efficacy and safety in open label settings. Its lead product candidate, KPT-8602 for solid tumors and KPT-1203 for hematological malignancies, uses its proprietary Permeation Enhancing Sequence (PES)-based lipophilic doxorubicin (DOX) prodrug platform to develop novel therapeutics with potential clinical and commercial applications. Karyopharm Therapeutics is also developing KRN2300 to treat patients with multiple myeloma.
Key slides for Karyopharm Therapeutics Inc
Jefferies Global Healthcare Conference 2025
Karyopharm Therapeutics Inc
Jefferies Global Healthcare Conference 2025
Karyopharm Therapeutics Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
KPTI
Country
🇺🇸 United States